心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Br J Haematol：肺动脉高压风险或与使用这些药物有关

2017-06-16 梁舒瑶 环球医学资讯

肺动脉高压药物
关注

肺动脉高压（PH）较为罕见，但它是使用酪胺酸激酶抑制剂（TKIs），如达沙替尼治疗患者的一种致命的不良事件，且未在使用伊马替尼或尼罗替尼的患者中进行过全面评价。2017年5月，发表在《Br J Haematol》的一项研究调查了使用伊马替尼、尼罗替尼、达沙替尼治疗患者的肺动脉高压的发生情况。

肺动脉高压（PH）较为罕见，但它是使用酪胺酸激酶抑制剂（TKIs），如达沙替尼治疗患者的一种致命的不良事件，且未在使用伊马替尼或尼罗替尼的患者中进行过全面评价。2017年5月，发表在《Br J Haematol》的一项研究调查了使用伊马替尼、尼罗替尼、达沙替尼治疗患者的肺动脉高压的发生情况。

研究者使用非侵入性超声心动图，评价了105例使用伊马替尼（n = 37）、尼罗替尼（n = 30）或达沙替尼（n = 38）治疗的慢性粒细胞白血病（CML）患者中PH的发病率。

伊马替尼组反映肺动脉压的平均三尖瓣反流峰梯度（TRPG）为22.7 mmHg，尼罗替尼组为23.1 mmHg，达沙替尼组为23.4 mmHg。这些值没有显着差异，但高于新确诊CML患者的值（19.0 mmHg）。105例患者中有9例患者监测出TRPG＞31 mmHg，标志可能发生PH：1例（2.7%）使用伊马替尼，3例（10.0%）使用尼罗替尼，5例（13.2%）使用达沙替尼。仅有3例患者抱怨呼吸困难，而其他6例无临床症状。此外，TRPG值与年龄或TKI疗程之间有一种倾向相关性。

这些结果表明，不仅是达沙替尼，伊马替尼和尼罗替尼也与亚临床PH之间存在相关性。非侵入性超声心动图有助于筛查PH，尤其是在年龄较大，长期接受TKI治疗的患者中。

原始出处：
Minami, M., et al.Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.Br J Haematol. 2017 May;177(4):578-587. doi: 10.1111/bjh.14608. Epub 2017 Mar 24.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008268, encodeId=740520082684e, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Feb 05 20:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925169, encodeId=fb4f1925169fb, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 09 11:46:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317310, encodeId=ef23131e310eb, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Jun 18 05:46:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211987, encodeId=dc0321198ed2, content=学习了，分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sat Jun 17 17:07:57 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211697, encodeId=bf1b21169e4b, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jun 17 00:14:36 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2018-02-05 一叶知秋

    #HAE#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2008268, encodeId=740520082684e, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Feb 05 20:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925169, encodeId=fb4f1925169fb, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 09 11:46:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317310, encodeId=ef23131e310eb, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Jun 18 05:46:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211987, encodeId=dc0321198ed2, content=学习了，分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sat Jun 17 17:07:57 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211697, encodeId=bf1b21169e4b, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jun 17 00:14:36 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2018-03-09 jklm09

    #动脉高压#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2008268, encodeId=740520082684e, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Feb 05 20:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925169, encodeId=fb4f1925169fb, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 09 11:46:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317310, encodeId=ef23131e310eb, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Jun 18 05:46:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211987, encodeId=dc0321198ed2, content=学习了，分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sat Jun 17 17:07:57 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211697, encodeId=bf1b21169e4b, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jun 17 00:14:36 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-18 fengyi812

    #EMA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2008268, encodeId=740520082684e, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Feb 05 20:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925169, encodeId=fb4f1925169fb, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 09 11:46:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317310, encodeId=ef23131e310eb, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Jun 18 05:46:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211987, encodeId=dc0321198ed2, content=学习了，分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sat Jun 17 17:07:57 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211697, encodeId=bf1b21169e4b, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jun 17 00:14:36 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 杨利洪

    学习了，分享了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2008268, encodeId=740520082684e, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Feb 05 20:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925169, encodeId=fb4f1925169fb, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 09 11:46:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317310, encodeId=ef23131e310eb, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Jun 18 05:46:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211987, encodeId=dc0321198ed2, content=学习了，分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sat Jun 17 17:07:57 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211697, encodeId=bf1b21169e4b, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jun 17 00:14:36 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 130****4638

    学习了谢谢分享。

    0

相关资讯

CHEST：特发性肺动脉高压与系统性硬化相关肺动脉高压的比较

此前的研究表明系统性硬化症（SSc）相关肺动脉高压（SSc-PAH）的生存要比特发性肺动脉高压（IPAH）更差。近期，一项发表在杂志CHEST的研究通过比较人口统计学、血液动力学、放射学特征以及疾病结局评估疾病之间的差异。此项研究招集651名诊断为IPAH或SSc相关的前毛细血管肺动脉高压的患者。确定患有肺部疾病或存在≥2个左心脏病相关风险因素的患者，最后剩下375名患者进行初步分析。亚组人群进行

Circulation：肺动脉高压的治疗靶点:尼克酰胺磷酸核糖转移酶

肺动脉高压是严重的进行性疾病，其标志之一是肺血管重塑。尼克酰胺磷酸核糖转移酶（NAMPT）可以调节细胞内NAD水平和细胞氧化还原状态，调节组蛋白去乙酰化酶，促进细胞增殖和抑制凋亡的细胞因子。我们猜测NAMPT可能促进肺血管重塑，而抑制NAMPT可以减轻肺动脉高压。

Lancet Respir Med：肺动脉高压患者血浆蛋白质组差异对预后影响

特发性和遗传性肺动脉高压是一种罕见的分子异质性疾病组。近日研究人员对于与特发性或遗传性肺动脉高压患者生存期相关的血浆蛋白浓度的差异进行研究以细化患者风险分层。研究从英国(队列1和队列2)、德国(队列3)和法国(队列4)招募特发性或遗传性肺动脉高压患者，在常规临床预约就诊时采集血样，采血30天内采集临床资料，采血7天内采集生化数据。对样本进行1129项血浆蛋白检测，研究确定了一组预后蛋白并通过选择性

Haematologica：脾切除术后心血管事件和肺动脉高压的风险如何？

总之，脾脏切除患者的卒中发生风险增加。此外，潜在的脾切除术相关疾病解释了脾切除术后心肌梗死、肺动脉高压风险增加的原因。

JACC：左主干冠状动脉狭窄与肺动脉高压和心绞痛相关性研究

左主干冠状动脉（LMCA）狭窄越来越多地被认为是肺动脉高压（PAH）导致心绞痛的主要原因之一。近日，在国际心血管权威杂志JACC上发表了一篇关于探索LMCA狭窄与肺动脉高压和心绞痛之间关系的临床研究。该研究旨在调查肺动脉高压和心绞痛或者有心绞痛临床表现患者的LMCA狭窄的流行病学情况，确定使用计算机断层扫描冠状动脉造影（CTCA）进行筛查的有效性，并对经皮冠状动脉介入治疗（PCIs）的安全性和有效

Nature Commun：TGF-β信号通路激活导致肺动脉高压的原因

血小板反应蛋白-1（thrombospondin-1, TSP-1）能够引起TGF-β信号通路的激活，而这一激活对于足够使血吸虫感染的小鼠发展肺动脉高压，并且是必需的。